453 related articles for article (PubMed ID: 23440415)
1. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
2. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy.
Khaitov M; Shilovskiy I; Valenta R; Weber M; Korneev A; Tulaeva I; Gattinger P; van Hage M; Hofer G; Konradsen JR; Keller W; Akinfenwa O; Poroshina A; Ilina N; Fedenko E; Elisyutina O; Litovkina A; Smolnikov E; Nikonova A; Rybalkin S; Aldobaev V; Smirnov V; Shershakova N; Petukhova O; Kudlay D; Shatilov A; Timofeeva A; Campana R; Udin S; Skvortsova V
Allergy; 2024 Apr; 79(4):1001-1017. PubMed ID: 37855043
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
4.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
5. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
6. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
7. Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1.
Akinfenwa O; Huang HJ; Linhart B; Focke-Tejkl M; Vrtala S; Poroshina A; Nikonova A; Khaitov M; Campion NJ; Eckl-Dorna J; Niederberger-Leppin V; Kratzer B; Tauber PA; Pickl WF; Kundi M; Campana R; Valenta R
Front Immunol; 2021; 12():744544. PubMed ID: 34795666
[TBL] [Abstract][Full Text] [Related]
8. Allergen hybrids - next generation vaccines for Fagales pollen immunotherapy.
Pichler U; Hauser M; Hofer H; Himly M; Hoflehner E; Steiner M; Mutschlechner S; Hufnagl K; Ebner C; Mari A; Briza P; Bohle B; Wiedermann U; Ferreira F; Wallner M
Clin Exp Allergy; 2014 Mar; 44(3):438-49. PubMed ID: 24330218
[TBL] [Abstract][Full Text] [Related]
9. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
[TBL] [Abstract][Full Text] [Related]
10. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.
Niespodziana K; Focke-Tejkl M; Linhart B; Civaj V; Blatt K; Valent P; van Hage M; Grönlund H; Valenta R
J Allergy Clin Immunol; 2011 Jun; 127(6):1562-70.e6. PubMed ID: 21411130
[TBL] [Abstract][Full Text] [Related]
11. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
12. Bet v 1--a Trojan horse for small ligands boosting allergic sensitization?
Asam C; Batista AL; Moraes AH; de Paula VS; Almeida FC; Aglas L; Kitzmüller C; Bohle B; Ebner C; Ferreira F; Wallner M; Valente AP
Clin Exp Allergy; 2014 Aug; 44(8):1083-93. PubMed ID: 24979350
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.
Linhart B; Narayanan M; Focke-Tejkl M; Wrba F; Vrtala S; Valenta R
Clin Exp Allergy; 2014 Feb; 44(2):278-87. PubMed ID: 24447086
[TBL] [Abstract][Full Text] [Related]
14. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.
Banerjee S; Weber M; Blatt K; Swoboda I; Focke-Tejkl M; Valent P; Valenta R; Vrtala S
J Immunol; 2014 May; 192(10):4867-75. PubMed ID: 24733847
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
17. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice.
Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U
PLoS One; 2012; 7(6):e39409. PubMed ID: 22768077
[TBL] [Abstract][Full Text] [Related]
18. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin.
Westritschnig K; Linhart B; Focke-Tejkl M; Pavkov T; Keller W; Ball T; Mari A; Hartl A; Stöcklinger A; Scheiblhofer S; Thalhamer J; Ferreira F; Vieths S; Vogel L; Böhm A; Valent P; Valenta R
J Immunol; 2007 Dec; 179(11):7624-34. PubMed ID: 18025208
[TBL] [Abstract][Full Text] [Related]
19. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
20. Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE responses in patients with birch pollen allergy.
Gepp B; Lengger N; Bublin M; Hemmer W; Breiteneder H; Radauer C
J Allergy Clin Immunol; 2014 Jul; 134(1):188-94. PubMed ID: 24529686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
